Deeside, United Kingdom
ADC Biotechnology is planning to build a 70,000-sf bioconjugation facility in Deeside in the United Kingdom. Featuring GMP production suites, the $11 million integrated facility will support the manufacture of antibody drug conjugates for all clinical phases as well as small-scale commercial production. The project will include space for R&D, process development, quality control, and warehousing. Operations will commence by December of 2018.
